Lyudmyla Berim, M.D.

Lyudmyla Berim, M.D.berim
Assistant Professor, Internal Medicine
Division of Oncology & Hematology

Academic Office mailing address:
UNMC Hematology/Oncolory Division
986840 Nebraska Medical Center
Omaha, NE 68198-6840

Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fax 402-559-6520

Practice Location:
Fred & Pamela Buffett Cancer Center
505 South 45th Street
Omaha, NE 68105 (map)

Hospital Appointments:
Nebraska Medicine
VA Nebraska-Western Iowa Health Care System

Education:
Ternopil Medical University, Ternopil, Ukraine, M.D. (1999)
Kherson University Hospital, Kershon, Ukraine, Resident (2000)
SUNY Buffalo, Buffalo, NY, Resident (2009)
Roswell Park Cancer Institute, Buffalo, NY, Fellow (2012)

Interests:
Novel therapies in the treatment of gastrointestinal malignancies

Biographical Sketch:
Dr. Berim is an Assistant Professor of Medicine at the University of Nebraska Medical Center. She received her MD degree in Ukraine, and completed her Internal Medicine Residency training at State University of New York at Buffalo. After finishing her Hematology/Oncology Fellowship at Roswell Park Cancer Institute in Buffalo, NY, she joined the UNMC faculty in 2014. Dr. Berim is actively engaged in medical practice, teaching and clinical research, and specializes in the care of patients with gastrointestinal malignancies, and carcinoma of unknown primary at the University of Nebraska Medical Center.

Publications:
Matta A, Tandra PK, Berim L. Priapism in a patient with sickle cell trait using     marijuana. BMJ Case Rep. 2014; May 5; 2014. PMID: 24798364

Derby, Lyudmyla; Czuczman, Myron S. Update on Novel Monoclonal Antibodies and Immunoconjugates for the Treatment of Lymphoproliferative Disorders. Future Oncol. 2011; Aug; 7 (8):963-79. PMID: 21823892

Lyudmyla Derby, Gopichand Pendurti, George Deeb, Sheila Sait, Annmarie Block, and Francisco J. Hernandez-Ilizaliturri. Blastoid Variant of Mantle Cell Lymphoma Is Associated with P53 Abnormalities and Have a Shorter Progression-Free Survival and Overall Survival Despite Upfront Chemo-Immunotherapy Followed by High Dose Chemotherapy and Autologous Stem Cell Support. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1773.

Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer 2010; Jan 1; 116(1):84-92. PMID: 19862816

Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter? A single-institution experience. Oncology 2009; 76(2):85-90. PMID: 19122466

Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed